Aging
Navigate
Submit an Article
Research Paper|Volume 12, Issue 20|pp. 20835–20861
SMARCD3 is a potential prognostic marker and therapeutic target in CAFs
Back to articleFigure 4(4 of 9)
100%
Figure 4
Figure 4.SMARCD3, CRIP2, PRAM1, HSPB2 and CERCAM could activate EMT in multiple cancer types (upper panel), while SMARCD3, CRIP2, PRAM1 and HSPB2 are associated with cell cycle inhibition (lower panel).